Zoetis (MEX:ZTS) Beneish M-Score: -2.47 (As of Jun. 26, 2026)


MEX:ZTS Zoetis Inc MEX:ZTS
71 GF Score
Price MXN1,371.70
GF Value MXN3,418.50
Valuation Significantly Undervalued
View Full Analysis

What is Zoetis Beneish M-Score?

Zoetis MEX:ZTS 71 Beneish M-Score is -2.47 as of Jun. 26, 2026. GuruFocus rates MEX:ZTS with a GF Score™ of 71/100 and a GF Value™ of MXN3,418.50 (Significantly Undervalued). Among 911 Drug Manufacturers companies, Zoetis ranks worse than 52.69% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.47 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zoetis's Beneish M-Score or its related term are showing as below:

MEX:ZTS' s Beneish M-Score Range Over the Past 10 Years
Min: -2.82   Med: -2.47   Max: -2.33
Current: -2.47

During the past 13 years, the highest Beneish M-Score of Zoetis was -2.33. The lowest was -2.82. And the median was -2.47.


Zoetis Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Zoetis's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zoetis Beneish M-Score Chart

Zoetis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.41 -2.35 -2.36 -2.57 -2.43

Zoetis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.52 -2.46 -2.48 -2.43 -2.47

MEX:ZTS vs UTHR, VTRS, NBIX: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zoetis Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zoetis's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zoetis's Beneish M-Score falls into.


MEX:ZTS
71GF Score
Zoetis Inc MEX:ZTS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zoetis Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zoetis for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0283+0.528 * 0.9876+0.404 * 0.9546+0.892 * 0.9485+0.115 * 1.0434
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9963+4.679 * -0.000968-0.327 * 1.1957
=-2.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was MXN27,157 Mil.
Revenue was 40789.967 + 42979.606 + 44026.08 + 46319.832 = MXN174,115 Mil.
Gross Profit was 29231.007 + 30159.548 + 31496.991 + 34099.681 = MXN124,987 Mil.
Total Current Assets was MXN116,744 Mil.
Total Assets was MXN273,268 Mil.
Property, Plant and Equipment(Net PPE) was MXN72,149 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN8,915 Mil.
Selling, General, & Admin. Expense(SGA) was MXN43,988 Mil.
Total Current Liabilities was MXN37,021 Mil.
Long-Term Debt & Capital Lease Obligation was MXN166,586 Mil.
Net Income was 10837.653 + 10857.437 + 13226.168 + 13519.366 = MXN48,441 Mil.
Non Operating Income was -414.752 + -594.188 + -311.851 + -997.948 = MXN-2,319 Mil.
Cash Flow from Operations was 7231.113 + 16079.09 + 17206.86 + 10506.694 = MXN51,024 Mil.
Total Receivables was MXN27,844 Mil.
Revenue was 44967.124 + 48322.657 + 47020.436 + 43253.763 = MXN183,564 Mil.
Gross Profit was 32323.956 + 33577.677 + 33217.536 + 31015.934 = MXN130,135 Mil.
Total Current Assets was MXN120,233 Mil.
Total Assets was MXN288,420 Mil.
Property, Plant and Equipment(Net PPE) was MXN74,897 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN9,709 Mil.
Selling, General, & Admin. Expense(SGA) was MXN46,547 Mil.
Total Current Liabilities was MXN69,251 Mil.
Long-Term Debt & Capital Lease Obligation was MXN110,474 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(27157.246 / 174115.485) / (27843.61 / 183563.98)
=0.155973 / 0.151683
=1.0283

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(130135.103 / 183563.98) / (124987.227 / 174115.485)
=0.708936 / 0.717841
=0.9876

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (116743.7 + 72148.833) / 273267.536) / (1 - (120232.841 + 74897.47) / 288419.704)
=0.308763 / 0.32345
=0.9546

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=174115.485 / 183563.98
=0.9485

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9708.956 / (9708.956 + 74897.47)) / (8915.254 / (8915.254 + 72148.833))
=0.114754 / 0.109978
=1.0434

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(43987.664 / 174115.485) / (46546.819 / 183563.98)
=0.252635 / 0.253573
=0.9963

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((166586.083 + 37021.133) / 273267.536) / ((110474.28 + 69251.007) / 288419.704)
=0.745084 / 0.623138
=1.1957

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(48440.624 - -2318.739 - 51023.757) / 273267.536
=-0.000968

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zoetis has a M-score of -2.59 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.47 mean?
Zoetis (MEX:ZTS) has a Beneish M-Score of -2.47 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Zoetis and its competitors. According to the industry distribution chart, Zoetis ranks #480 out of 911 companies in the Drug Manufacturers industry, placing it in the top 52.7%.
Is Zoetis' Beneish M-Score too high?
Zoetis' current Beneish M-Score is -2.47. Based on the distribution chart, Zoetis ranks #480 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zoetis has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Beneish M-Score compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #480 out of 911 companies for Beneish M-Score. This places Zoetis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Zoetis and its competitors. Zoetis's current Beneish M-Score is -2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (MEX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN3,418.50, compared to a current price of MXN1,371.70 — trading 59.9% below its estimated fair value. The current Beneish M-Score is -2.47. Zoetis' overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Zoetis (MEX:ZTS), the current Beneish M-Score is -2.47 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zoetis (MEX:ZTS) Overvalued in 2026?

Based on GuruFocus' analysis, Zoetis stock appears to be undervalued. The current stock price of MXN1,371.70 is trading 59.9% below its estimated GF Value™ of MXN3,418.50. GuruFocus considers Zoetis to be Significantly Undervalued.

Key valuation signals for MEX:ZTS:

  • Beneish M-Score: -2.47
  • GF Value™: MXN3,418.50 vs. price of MXN1,371.70 (59.9% below fair value)
  • GF Score™: 71/100

No single metric tells the full story. See the MEX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zoetis Business Description

Address 10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
71GF Score

Get the complete analysis for MEX:ZTS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,371.70
Price
MXN3,418.50
GF Value